1. Market Research
  2. > Healthcare Market Trends
  3. > Drug Addiction Partnering 2010-2015

Drug Addiction Partnering 2010-2015

  • May 2015
  • -
  • Currentpartnering
  • -
  • 100 pages

Summary
Drug Addiction Partnering 2009-2014 report provides understanding and access to the drug addiction partnering deals and agreements entered into by the worlds leading healthcare companies.


Description

Drug Addiction Partnering 2009-2014 report provides understanding and access to the drug addiction partnering deals and agreements entered into by the worlds leading healthcare companies.

•Trends in drug addiction partnering deals
•Top drugs deal addiction by value
•Deals listed by company A-Z, industry sector, stage of development, technology type

Drug Addiction Partnering 2009-2014 provides understanding and access to the drug addiction partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of drug addiction partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors drug addiction technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This data driven report contains over 30 links to online copies of actual drug addiction deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of drug addiction partnering trends.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in drug addiction partnering since 2009, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.

Chapter 3 provides an overview of the leading drug addiction deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive directory of drug addiction partnering deals signed and announced since 2009. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of drug addiction technologies and products.

Report scope

Drug Addiction Partnering 2009-2014 is intended to provide the reader with an in-depth understanding and access to drug addiction trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

•Trends in drug addiction dealmaking in the biopharma industry since 2009
•Access to summary headline, upfront, milestone and royalty data
•The leading drug addiction deals by value since 2009

In Drug Addiction Partnering 2009-2014, the available deals are listed by:
•Headline value
•Upfront payment value
•Royalty rate value
•Company A-Z
•Industry sector
•Stage of development at signing
•Deal component type
•Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


Benefits

Drug Addiction Partnering 2009-2014 provides the reader with the following key benefits:


•In-depth understanding of drug addiction deal trends since 2009
•Access to summary headline, upfront, milestone and royalty data
•Comprehensive access to over 30 actual drug addiction deals entered into by the world’s biopharma companies since 2009
•Insight into key deal terms included in contracts, where disclosed
•Understand the key deal terms companies have agreed in deals
•Undertake due diligence to assess suitability of your proposed deal terms for partner companies


Keywords

drug addiction, public health, partnering, licensing, deals, alliances, merger and acquisition, M&A, big pharma

Table Of Contents

Drug Addiction Partnering 2010-2015
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in drug addiction partnering

2.1. Introduction
2.2. Drug addiction partnering over the years
2.3. Big pharma drug addiction dealmaking activity
2.4. Big biotech drug addiction dealmaking activity
2.5. Most active drug addiction dealmakers
2.6. Drug addiction partnering by deal type
2.7. Drug addiction partnering industry sector
2.8. Drug addiction partnering by stage of development
2.9. Drug addiction partnering by technology type
2.10. Disclosed financial deal terms for drug addiction
2.10.1 Drug addiction headline values
2.10.2 Drug addiction upfront payments
2.10.3 Drug addiction milestone payments
2.10.4 Drug addiction royalty rates

Chapter 3 - Leading drug addiction deals

3.1. Introduction
3.2. Top drug addiction deals by value

Chapter 4 - Dealmaking directory

4.1. Introduction
4.2. Company A-Z
4.3. By deal type
4.4. By industry sector
4.5. By stage of development
4.6. By technology type

Chapter 5 - Partnering resource center

5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking

Appendices

Appendix 1 - Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering
Order Form - Reports
Order Form - Subscription Access Products

Table of figures

Figure 1: Drug addiction partnering since 2009
Figure 2: Big pharma - top 50 - drug addiction deals 2009 to 2014
Figure 3: Big pharma drug addiction deal frequency - 2009 to 2014
Figure 4: Big biotech - top 50 - drug addiction deals 2009 to 2014
Figure 5: Big biotech drug addiction deal frequency - 2009 to 2014
Figure 6: Drug addiction dealmaking activity- 2009 to 2014
Figure 7: Drug addiction partnering by deal type since 2009
Figure 8: Drug addiction partnering by industry sector since 2009
Figure 9: Drug addiction partnering by stage of development since 2009
Figure 10: Drug addiction partnering by technology type since 2009
Figure 11: Drug addiction deals with a headline value
Figure 12: Drug addiction deals with upfront payment values
Figure 13: Drug addiction deals with milestone payments
Figure 14: Drug addiction deals with royalty rates, %
Figure 15: Top drug addiction deals by value since 2009
Figure 16: Online partnering resources
Figure 17: Forthcoming partnering events
Figure 18: Deal type definitions

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,000 pages and 550 tables, and provides granular data and analysis not available from any other published source. The survey is designed ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.